Bukwang Pharmaceutical Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Jae-Young Lee
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | 18.6yrs |
Recent management updates
Recent updates
Bukwang Pharmaceutical (KRX:003000) Has Debt But No Earnings; Should You Worry?
Nov 13
Is Bukwang Pharmaceutical (KRX:003000) Weighed On By Its Debt Load?
May 22Investors In Bukwang Pharmaceutical Co., Ltd. (KRX:003000) Should Consider This, First
Apr 03Did Bukwang Pharmaceutical's (KRX:003000) Share Price Deserve to Gain 71%?
Mar 08Is Bukwang Pharmaceutical (KRX:003000) A Risky Investment?
Feb 10How Much Of Bukwang Pharmaceutical Co., Ltd. (KRX:003000) Do Insiders Own?
Jan 14Does It Make Sense To Buy Bukwang Pharmaceutical Co., Ltd. (KRX:003000) For Its Yield?
Dec 19Did You Miss Bukwang Pharmaceutical's (KRX:003000) 90% Share Price Gain?
Nov 23CEO
Jae-Young Lee
less than a year
Tenure
Jae-Young Lee is Chief Executive Officer of Bukwang Pharmaceutical Co. Ltd. from 2024.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & Director | no data | no data | no data | |
| Managing Director and Director | 18.6yrs | no data | no data | |
| Senior Managing Director | no data | no data | no data | |
| Chairperson | 18.6yrs | no data | 10.3% ₩ 32.6b | |
| Vice Chairman | 18.6yrs | no data | no data | |
| Representative Director | no data | no data | no data | |
| Independent Outside Director | no data | no data | no data | |
| Independent Outside Director | no data | no data | no data | |
| Independent Outside Director | no data | no data | no data |
18.6yrs
Average Tenure
70yo
Average Age
Experienced Board: A003000's board of directors are seasoned and experienced ( 18.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 08:07 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bukwang Pharmaceutical Co., Ltd. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jin Kyun Lim | IBK Securities Co. Ltd. |
| JongHoon Lee | Mirae Asset Securities Co., Ltd. (Pre-Merger) |
| Seung Kim | Samsung Securities Co. Ltd. |